FTD, or frontotemporal dementia, is diagnosed through a combination of clinical evaluation, neuropsychological testing, and brain imaging, but reaching that diagnosis often takes 3.6 years on average, with visits to three or more doctors along the way. Unlike Alzheimer’s disease, there is no single test that confirms FTD. Instead, doctors piece together behavioral changes, language problems, cognitive test results, and brain scans to distinguish it from other conditions that can look remarkably similar.
Why FTD Is So Hard to Diagnose
FTD typically strikes between ages 45 and 65, earlier than most dementias, and its initial symptoms often look like psychiatric illness rather than neurodegeneration. In one study of patients with the behavioral variant of FTD, 71.4% were initially misdiagnosed with a psychiatric disorder rather than dementia. Women were most commonly misdiagnosed with depression or bipolar disorder, while men were more often labeled with anxiety disorders or psychotic disorders.
These misdiagnoses aren’t careless mistakes. Early FTD can cause personality shifts, impulsive behavior, emotional blunting, or social withdrawal that genuinely resemble mood and psychiatric conditions. One caregiver described years of diagnoses ranging from “generic stress to menopause-related anxiety and depression” before FTD was identified. By the time the correct diagnosis arrived, the disease had already progressed significantly. This pattern is common: many families report that their loved one’s FTD was too advanced by the time of diagnosis for them to participate in clinical research or benefit from early intervention strategies.
The Two Main Types of FTD
FTD is an umbrella term covering several distinct syndromes, but the two broad categories are behavioral variant FTD and primary progressive aphasia (PPA), which primarily affects language.
Behavioral variant FTD is the most common form. It causes progressive changes in personality, judgment, and social behavior. People may lose empathy, act impulsively, develop compulsive habits, or become apathetic. These changes reflect damage to the brain’s frontal lobes, which govern decision-making and social behavior.
Primary progressive aphasia involves a gradual loss of language ability and comes in three recognized variants. The nonfluent variant causes effortful, halting speech with grammatical errors and inconsistent sound distortions. The semantic variant leaves speech fluent but strips away word meaning: a person can speak smoothly but can’t name objects or understand individual words. The logopenic variant falls somewhere between, characterized by frequent pauses during speech due to severe word-finding difficulty, along with trouble repeating sentences. Each variant reflects damage to different language-related brain regions.
How Doctors Evaluate for FTD
Diagnosis typically begins with a detailed history from both the patient and someone close to them, since people with FTD often don’t recognize their own behavioral changes. A neurologist or behavioral neurologist will look for patterns: when did symptoms start, how have they progressed, and which areas of function are affected?
Neuropsychological testing helps map cognitive strengths and weaknesses. FTD patients tend to have greater difficulties with language and certain executive functions (planning, mental flexibility, impulse control) while their memory may remain relatively intact early on. Alzheimer’s patients, by contrast, typically show more prominent memory loss. In research comparing the two groups, FTD patients performed better on delayed memory recall tasks but worse on tests of verbal fluency, such as naming as many animals as possible in one minute. Interestingly, some executive function tests don’t reliably separate the two diseases. One large study found that, apart from memory, standard cognitive test batteries “did not define distinct patterns” cleanly distinguishing FTD from Alzheimer’s. This is part of why diagnosis requires more than test scores alone.
One reliable clue is the presence of neuropsychiatric symptoms. FTD patients consistently show a higher number of behavioral disturbances, including agitation, disinhibition, and apathy, compared to those with Alzheimer’s at similar stages.
What Brain Imaging Reveals
Brain scans play a critical role in supporting an FTD diagnosis and ruling out other causes. On MRI, FTD typically shows shrinkage concentrated in the frontal and temporal lobes, the brain regions behind the forehead and around the temples. The back of the brain tends to be relatively spared. In many cases the right side of the brain shows more extensive shrinkage than the left.
This pattern contrasts with Alzheimer’s disease, where shrinkage and reduced brain activity concentrate in the temporal and parietal lobes (the areas toward the back and sides of the brain). A specialized type of PET scan that measures brain metabolism can sharpen the distinction further. In FTD, reduced activity targets the front and underside of the frontal lobes along with the front portions of the temporal lobes. In Alzheimer’s, the hallmark finding is reduced activity in both temporal and parietal regions bilaterally. Blood flow imaging shows a similar split: FTD produces reduced blood flow predominantly in the frontal lobes, often worse on the right side, while Alzheimer’s shows reduced flow mainly in the temporal lobes.
No imaging finding alone confirms FTD, but these patterns, combined with clinical symptoms and test results, build the case for diagnosis.
Blood and Spinal Fluid Biomarkers
A protein called neurofilament light chain, released when nerve cells are damaged, is showing promise as a diagnostic tool for FTD. When measured in spinal fluid, it distinguishes behavioral variant FTD from psychiatric disorders with high accuracy, correctly identifying FTD in 63% to 96% of cases while correctly ruling it out in 81% to 100% of non-FTD cases. Blood-based measurement is slightly less precise but still useful, with correct identification rates of 65% to 100%. This biomarker is particularly valuable because the biggest diagnostic challenge is separating early FTD from psychiatric conditions like depression or bipolar disorder, exactly the scenario where neurofilament light chain performs well.
The Role of Genetics
FTD has a stronger genetic component than many other dementias. About 15% of familial FTD cases are caused by inherited mutations in one of three genes. The most common is a repeat expansion in a gene called C9orf72, which accounts for 63% to 89% of identified genetic FTD cases depending on the study. Mutations in a gene called GRN (which produces a growth factor protein) account for 6% to 26%, and mutations in MAPT (which produces a protein involved in brain cell structure) account for 5% to 11%.
Genetic testing doesn’t diagnose FTD on its own, but finding one of these mutations in someone with compatible symptoms strongly supports the diagnosis. It also has implications for family members, since these mutations follow dominant inheritance patterns, meaning each child of a carrier has a 50% chance of inheriting the variant. Genetic counseling is typically offered when a known familial pattern exists.
What the Diagnostic Process Looks Like
For most people, getting an FTD diagnosis is not a single appointment but a process that unfolds over months or years. It usually involves a primary care visit where concerns are first raised, referral to a neurologist, neuropsychological testing that can take several hours, at least one MRI, and sometimes additional PET scans or spinal fluid analysis. Some people see a psychiatrist first if behavioral symptoms are the initial concern, which can add time if FTD isn’t considered early.
Specialized memory clinics and academic medical centers with expertise in FTD tend to reach accurate diagnoses faster. If you or a family member are in the process of evaluation and standard psychiatric treatments aren’t helping, or if personality changes seem to be progressing rather than episodic, raising the possibility of FTD directly with your neurologist can help move the process forward. The Association for Frontotemporal Degeneration maintains a directory of knowledgeable clinicians, which can be a practical starting point for families navigating this path.